Regeneron Pharmaceuticals Inc. REGN said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a 154-patient study of the drug, about 34% of Ebola patients died after 28 days, compared with 51% of patients who did not receive the drug, Regeneron said. The company received recent attention after President Donald Trump praised Regeneron’s experimental COVID-19 treatment that he received. Regeneron shares are up 60% for the year, compared with an 8% gain by the S&P 500 index SPX.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
